OBJECTIVE: To determine the average costs per child for rotavirus (RV) acute gastroenteritis from different perspectives, from the hospital's, third-party payer's, pediatrician's and family's perspectives as well as in summary from the societal one. MATERIALS AND METHODS: This cost-of-illness study is based on data collected alongside a 6-month prospective, laboratory-confirmed epidemiologic study that evaluated the disease burden of RV infection in Austrian children < or =48 months of age. The study population at risk to contract a community- and nosocomially acquired acute gastroenteritis comprised 9,687 children. All of the 51 children with community-acquired and 33 with nosocomially acquired RV acute gastroenteritis were included in this analysis. The annual costs were estimated by means of extrapolation. RESULTS: For community-acquired RV acute gastroenteritis, the average costs from the hospital's perspective were EURO (EUR) 97.8, from the third party payer's perspective 95.6 EUR, followed by 29.9 EUR and 9.8 EUR from the family's and pediatrician's perspectives, respectively. For nosocomially acquired RV acute gastroenteritis the average costs from the hospital's perspective were 1,494 EUR and from the third party payer's and family's perspectives 831 EUR and 116.8 EUR, respectively. In summary the average costs from the societal point of view for community-acquired RV acute gastroenteritis were 250 EUR and for nosocomial infections 2,442 EUR. After extrapolation the estimated total annual costs were 7.17 EUR million to 0.97 EUR million (13.6%) caused by community-acquired RV acute gastroenteritis and 6.2 EUR million (86.4%) caused by nosocomial RV acute gastroenteritis. CONCLUSION: This cost-of-illness study clearly demonstrates the great impact of RV acute gastroenteritis, mainly of nosocomially acquired infection, on medical health care costs in Austria. To cut costs efforts in disease prevention should be encouraged.
OBJECTIVE: To determine the average costs per child for rotavirus (RV) acute gastroenteritis from different perspectives, from the hospital's, third-party payer's, pediatrician's and family's perspectives as well as in summary from the societal one. MATERIALS AND METHODS: This cost-of-illness study is based on data collected alongside a 6-month prospective, laboratory-confirmed epidemiologic study that evaluated the disease burden of RV infection in Austrian children < or =48 months of age. The study population at risk to contract a community- and nosocomially acquired acute gastroenteritis comprised 9,687 children. All of the 51 children with community-acquired and 33 with nosocomially acquired RV acute gastroenteritis were included in this analysis. The annual costs were estimated by means of extrapolation. RESULTS: For community-acquired RV acute gastroenteritis, the average costs from the hospital's perspective were EURO (EUR) 97.8, from the third party payer's perspective 95.6 EUR, followed by 29.9 EUR and 9.8 EUR from the family's and pediatrician's perspectives, respectively. For nosocomially acquired RV acute gastroenteritis the average costs from the hospital's perspective were 1,494 EUR and from the third party payer's and family's perspectives 831 EUR and 116.8 EUR, respectively. In summary the average costs from the societal point of view for community-acquired RV acute gastroenteritis were 250 EUR and for nosocomial infections 2,442 EUR. After extrapolation the estimated total annual costs were 7.17 EUR million to 0.97 EUR million (13.6%) caused by community-acquired RV acute gastroenteritis and 6.2 EUR million (86.4%) caused by nosocomial RV acute gastroenteritis. CONCLUSION: This cost-of-illness study clearly demonstrates the great impact of RV acute gastroenteritis, mainly of nosocomially acquired infection, on medical health care costs in Austria. To cut costs efforts in disease prevention should be encouraged.
Authors: Emily R Smith; Emily E Rowlinson; Volga Iniguez; Kizee A Etienne; Rosario Rivera; Nataniel Mamani; Rick Rheingans; Maritza Patzi; Percy Halkyer; Juan S Leon Journal: Vaccine Date: 2011-09-02 Impact factor: 3.641
Authors: P K Lorgelly; D Joshi; M Iturriza Gómara; C Flood; C A Hughes; J Dalrymple; J Gray; M Mugford Journal: Epidemiol Infect Date: 2007-03-05 Impact factor: 2.451
Authors: Marta Bouzón-Alejandro; Lorenzo Redondo-Collazo; Juan Manuel Sánchez-Lastres; Nazareth Martinón-Torres; José María Martinón-Sánchez; Federico Martinón-Torres Journal: BMC Pediatr Date: 2011-09-14 Impact factor: 2.125
Authors: Isla Ogilvie; Hanane Khoury; Mireille M Goetghebeur; Antoine C El Khoury; Carlo Giaquinto Journal: BMC Infect Dis Date: 2012-03-19 Impact factor: 3.090
Authors: Nicole Mittmann; Marika Koo; Nick Daneman; Andrew McDonald; Michael Baker; Anne Matlow; Murray Krahn; Kaveh G Shojania; Edward Etchells Journal: Drug Healthc Patient Saf Date: 2012-10-05
Authors: Aneta Nitsch-Osuch; Ernest Kuchar; Anna Kosmala; Katarzyna Zycinska; Kazimierz Wardyn Journal: Arch Med Sci Date: 2013-02-10 Impact factor: 3.318